Literature DB >> 15452760

Direct medical costs unequivocally related to diabetes in Italian specialized centers.

Livio Garattini1, Francesca Chiaffarino, Dante Cornago, Carlo Coscelli, Fabio Parazzini.   

Abstract

This study estimated the resource utilization and direct medical costs in Italian diabetes centers (DCs). Hospital admissions for major chronic complications were not considered since DCs deliver primary care and follow up only complications unequivocally related to diabetes-acute complications and diabetic foot. The multicenter, prospective, observational study involving 31 Italian DCs included a total of 1,910 patients classified into eight prognostic groups by type of diabetes (types 1 and 2), metabolic control (HbA1c >7.5%, HbA1c < or =7.5%) and age (< or =60, >60). The average total cost of type 1 diabetes per patient per year ranged from 762 euro in group 2 (age < or =60, HbA1c >7.5%) to 1,060 euro in group 4 (age >60, HbA1c >7.5%), and that the cost of type 2 diabetes from 423 euro in group 5 (age < or =60, HbA1c < or =7.5%) to 613 euro in group 8 (age >60, HbA1c >7.5%). The study brought to light the wide variability in the single cost components across clinically defined groups of patients. The cost of diabetes management in the strict sense was significantly affected by the type of diabetes and metabolic control.

Entities:  

Mesh:

Year:  2004        PMID: 15452760     DOI: 10.1007/s10198-003-0188-z

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  23 in total

1.  How do Italian pharmacoeconomists evaluate indirect costs?

Authors:  L Garattini; F Tediosi; S Ghislandi; L Orzella; C Rossi
Journal:  Value Health       Date:  2000 Jul-Aug       Impact factor: 5.725

Review 2.  The economic costs of NIDDM.

Authors:  T J Songer
Journal:  Diabetes Metab Rev       Date:  1992-12

3.  Diabetes: the cost of illness in Sweden.

Authors:  F Henriksson; B Jönsson
Journal:  J Intern Med       Date:  1998-12       Impact factor: 8.989

4.  Evaluation of a mini-column chromatographic procedure for the measurement of hemoglobin A1c.

Authors:  P K Jaynes; M C Willis; P P Chou
Journal:  Clin Biochem       Date:  1985-02       Impact factor: 3.281

5.  Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered.

Authors:  A Norlund; J Apelqvist; P O Bitzén; P Nyberg; B Scherstén
Journal:  J Intern Med       Date:  2001-07       Impact factor: 8.989

6.  Assessing the impact of complications on the costs of Type II diabetes.

Authors:  R Williams; L Van Gaal; C Lucioni
Journal:  Diabetologia       Date:  2002-06-12       Impact factor: 10.122

7.  Health care expenditures for people with diabetes mellitus, 1992.

Authors:  R J Rubin; W M Altman; D N Mendelson
Journal:  J Clin Endocrinol Metab       Date:  1994-04       Impact factor: 5.958

8.  An Italian population-based study of the prevalence of diabetes: some methodological aspects.

Authors:  M P Garancini; G Calori; E Manara; A Izzo; E Ebbli; L Galli; L Boari; G Gallus
Journal:  Diabete Metab       Date:  1993

9.  Prevalence of diabetes mellitus and impaired glucose tolerance in a rural area of Italy.

Authors:  A Verrillo; A de Teresa; S La Rocca; P C Giarrusso
Journal:  Diabetes Res       Date:  1985-11

10.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.